? GENOMICS SHARED RESOURCE (GSR) The mission of the GSR is to support OSUCCC members and high-impact cancer research projects with genomics expertise, instrumentation and centralized resources to generate high-quality data. The GSR is a state- of-the-art genomics laboratory that has substantially increased capacity through expansion to shared resources at Nationwide Children?s Hospital. The GSR has the following Specific Aims: 1) sequence DNA and RNA templates using both next generation sequencing platforms (i.e. Ilumina HiSeq4000 and NovaSeq6000) and capillary Sanger sequencing and genotyping (via ABI 3730XL DNA Analyzers); 2) use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (NanoString) and microarray (Affymetrix) platforms; and 3) perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants, gene expression, and small insertion/deletion polymorphisms including quantitative PCR (QuantStudio 12K flex) and high-throughput digital and custom PCR assay (BiomarkHD and Juno) technologies. In 2018, the GSR partnered with the Institute for Genomic Medicine (IGM) at Nationwide Children?s Hospital (NCH) to expand our next-generation sequencing (NGS) technology services. The GSR co-Directors are Drs. Amanda Toland (MCC) and Richard Wilson (CB). The GSR provides essential genomics expertise and instrumentation to members of all five programs. During the current funding cycle, the GSR contributed to 338 publications (63 > 10 impact factor) and 94 grants from members of all five programs. We have been highly responsive to changing technology and user needs and, as a result, we now offer Sanger sample pick-up, cell line verification, and single-cell (sc) RNA sequencing. We also regularly host technology- based seminars or workshops to introduce new technology to OSUCCC members. With OSUCCC and institutional support, we have expanded our facilities to improve sequencing capabilities and to include nanofluidics liquid handlers and library preparation systems for sc-sequencing to provide state-of-the-art resolution in cancer biology and response to therapy. In the next funding cycle, the GSR will support the genomics needs of all OSU strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. New services under development include isolation of circulating tumor cells for down-stream culturing and genomic profiling, purchasing an instrument and developing protocols for spatial transcriptomics, purchasing an instrument for sc-DNA sequencing, and optimizing protocols for other sc-genomics and low-input NanoString applications. The annual budget of the GSR is $2,634,443, yet the CCSG request is $231,495. As such, the GSR leverages extensive institutional support and seeks only 8.8% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090011
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Wang, Yufeng; Dong, Wenjuan; Zhang, Yibo et al. (2018) Dependence of innate lymphoid cell 1 development on NKp46. PLoS Biol 16:e2004867

Showing the most recent 10 out of 2602 publications